Coverage from AAPS PharmSci 360 and CPHI Milan featured discussion about impurities, devices, and supply resilience. This week also included topics such as AI accountability, oral peptides, and new licensing deals.
News|Articles|November 1, 2024
- Pharmaceutical Technology, November 2024
- Volume 48
- Issue 11
- Pages: 8
Single-use ADC Reactor
Author(s)Pharmaceutical Technology Editors
The Mobius ADC Reactor is the first single-use reactor designed specifically for the manufacture of antibody drug conjugates.
MilliporeSigma, the US and Canada Life Science business of Merck KGaA, Darmstadt, Germany, introduced the Mobius ADC Reactor, a single-use reactor designed specifically for the manufacture of antibody drug conjugates (ADCs). The reactor is the first of its kind for ADC production, according to the company. The Mobius ADC Reactor is designed to meet the unique requirements for linking the necessary components for ADCs and aims to enable these critical therapies to be produced faster and more safely with faster turnaround times and fewer cross-contamination risks. Performance improvements using the single-use reactor include elimination of potent liquid waste and a 70% increase in efficiency. The reactor’s single-use assemblies are made of Ultimus Film technology, which provides enhanced bag strength, improved durability, and leak resistance.
Articles in this issue
about 2 years ago
Increasing Processing Flexibility to Meet Demandabout 2 years ago
Automate Aseptic Filling: Closing the System at Full Modularityabout 2 years ago
Untethered Data: Unifying and Contextualizing Drug Discovery Dataabout 2 years ago
Strategies for Overcoming Common Challenges in Tech Transferabout 2 years ago
Weathering the Stormsabout 2 years ago
The Importance of Appropriate Supplier Oversightabout 2 years ago
Fixed Tank Dual Shaft Mixer/Pressure Reactorabout 2 years ago
Aseptic Micro-ConnectorRelated to this article
CDMOs, OEMs, and Used Equipment Resellers are Joining Forces to Onshore Pharmaceutical Manufacturing
Onshoring pharmaceutical manufacturing can be made more practical by collaborating with CDMOs that have gray space, supported by strong relationships with used equipment dealers and OEMs.
The FDA grants accelerated approval to subcutaneous amivantamab for head and neck cancer, extending the IV-to-subcutaneous shift in biologics formulation.
USP data show fewer US drug shortages but longer ones, averaging 5+ years. Drug shortages are an incentive problem, not a manufacturing mystery.
Almac Clinical Services’ clinical supply strategy won the 2026 CPHI Award for Supply Chain Excellence. Nishma Patel, supply chain solutions manager, explains the benefits and challenges of the company’s just-in-time manufacturing solution.
The pharmaceutical supply chain is a complex system with high stakes. USP provides insights on how it is helping industry navigate global disruptions and procurement issues.
CDMOs announced expansions, exhibitors showcased automated equipment, and supply chain strategy discussions were a focus at CPHI Milan 2026.
Mitigating nitrosamine risk requires assessing each product individually and chasing zero nitrite in pharmaceutical excipients is often impractical and costly.
Trending on Pharmaceutical Technology
1
Why Drug Shortages Average 5+ Years: PharmTech Explained
2
CDMOs, OEMs, and Used Equipment Resellers are Joining Forces to Onshore Pharmaceutical Manufacturing
3
$1.15B AI-Guided Macrocycle Discovery Lands at argenx
4
Drapeau’s AI Deep Dive: Qualify the Reviewer Before the AI Goes Live
5